JP2021513536A5 - - Google Patents

Info

Publication number
JP2021513536A5
JP2021513536A5 JP2020542822A JP2020542822A JP2021513536A5 JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5 JP 2020542822 A JP2020542822 A JP 2020542822A JP 2020542822 A JP2020542822 A JP 2020542822A JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5
Authority
JP
Japan
Prior art keywords
domain
composition according
linker
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542822A
Other languages
English (en)
Japanese (ja)
Other versions
JP7279054B2 (ja
JP2021513536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/053136 external-priority patent/WO2019154986A1/en
Publication of JP2021513536A publication Critical patent/JP2021513536A/ja
Publication of JP2021513536A5 publication Critical patent/JP2021513536A5/ja
Priority to JP2023077703A priority Critical patent/JP2023113648A/ja
Application granted granted Critical
Publication of JP7279054B2 publication Critical patent/JP7279054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542822A 2018-02-09 2019-02-08 Edb標的化il-12組成物 Active JP7279054B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077703A JP2023113648A (ja) 2018-02-09 2023-05-10 Edb標的化il-12組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18156141 2018-02-09
EP18156141.6 2018-02-09
EP18179313 2018-06-22
EP18179313.4 2018-06-22
PCT/EP2019/053136 WO2019154986A1 (en) 2018-02-09 2019-02-08 Edb targeting il-12 compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077703A Division JP2023113648A (ja) 2018-02-09 2023-05-10 Edb標的化il-12組成物

Publications (3)

Publication Number Publication Date
JP2021513536A JP2021513536A (ja) 2021-05-27
JP2021513536A5 true JP2021513536A5 (cg-RX-API-DMAC7.html) 2022-01-31
JP7279054B2 JP7279054B2 (ja) 2023-05-22

Family

ID=65268973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542822A Active JP7279054B2 (ja) 2018-02-09 2019-02-08 Edb標的化il-12組成物
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Edb標的化il-12組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Edb標的化il-12組成物

Country Status (25)

Country Link
US (1) US12173044B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749372B1 (cg-RX-API-DMAC7.html)
JP (2) JP7279054B2 (cg-RX-API-DMAC7.html)
KR (2) KR102488801B1 (cg-RX-API-DMAC7.html)
CN (1) CN111683687B (cg-RX-API-DMAC7.html)
AU (2) AU2019219201B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012888A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087488C (cg-RX-API-DMAC7.html)
CL (1) CL2020002052A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009737A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200342A (cg-RX-API-DMAC7.html)
CU (1) CU20200054A7 (cg-RX-API-DMAC7.html)
EC (1) ECSP20047171A (cg-RX-API-DMAC7.html)
ES (1) ES3035714T3 (cg-RX-API-DMAC7.html)
IL (1) IL275713A (cg-RX-API-DMAC7.html)
JO (1) JOP20200193A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008231A (cg-RX-API-DMAC7.html)
MY (1) MY200700A (cg-RX-API-DMAC7.html)
PE (1) PE20210122A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551230A1 (cg-RX-API-DMAC7.html)
RU (2) RU2758143C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006334XA (cg-RX-API-DMAC7.html)
TW (1) TWI844524B (cg-RX-API-DMAC7.html)
UY (1) UY38074A (cg-RX-API-DMAC7.html)
WO (1) WO2019154986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
KR102524247B1 (ko) 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
US20230312726A1 (en) * 2020-04-14 2023-10-05 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법
US20250073239A1 (en) * 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
EP4780495A1 (en) 2023-09-19 2026-07-29 Philochem AG Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
MX2007013875A (es) 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
ES2872964T3 (es) * 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
JP2016519111A (ja) * 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
AU2018226215B2 (en) 2017-02-24 2019-11-21 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
EP3634999A1 (en) * 2017-06-07 2020-04-15 Philogen S.p.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物

Similar Documents

Publication Publication Date Title
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2024526145A5 (cg-RX-API-DMAC7.html)
JP2023507190A5 (cg-RX-API-DMAC7.html)
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2018518454A5 (cg-RX-API-DMAC7.html)
JP2016518387A5 (cg-RX-API-DMAC7.html)
JP2002544238A5 (cg-RX-API-DMAC7.html)
JP2019520426A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
TW202214243A (zh) 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用
JP2017537927A5 (cg-RX-API-DMAC7.html)
CN109985237A (zh) 一种治疗结直肠癌的药物组合物及其应用
RU2017146346A (ru) Комбинированная терапия pac-1
Razak et al. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: ARA Razak et al.
JP2023524789A5 (cg-RX-API-DMAC7.html)
JP2024016209A5 (cg-RX-API-DMAC7.html)
JP2008500277A5 (cg-RX-API-DMAC7.html)
Vaisitti et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter's syndrome (RS)
JP2023524359A5 (cg-RX-API-DMAC7.html)
JP2024028756A5 (cg-RX-API-DMAC7.html)
JP2018537433A5 (cg-RX-API-DMAC7.html)
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2022526525A5 (cg-RX-API-DMAC7.html)
JP2015510945A5 (cg-RX-API-DMAC7.html)